Aethlon Medical, Inc. (NASDAQ:AEMD) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Analysts have set a 12-month consensus price objective of $4.88 for the company and are forecasting that the company will post ($0.07) EPS for the current quarter, according to Zacks. Zacks has also given Aethlon Medical an industry rank of 54 out of 255 based on the ratings given to its competitors.
A number of equities analysts recently issued reports on the company. HC Wainwright set a $3.00 price objective on Aethlon Medical and gave the company a “buy” rating in a report on Thursday, August 9th. ValuEngine cut Aethlon Medical from a “buy” rating to a “hold” rating in a report on Monday, July 2nd.
Shares of Aethlon Medical stock opened at $1.16 on Wednesday. The company has a market capitalization of $21.00 million, a PE ratio of -2.52 and a beta of 2.01. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.49 and a quick ratio of 13.49. Aethlon Medical has a one year low of $0.79 and a one year high of $2.04.
Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings data on Wednesday, August 8th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.02. The business had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.11 million. As a group, research analysts forecast that Aethlon Medical will post -0.27 earnings per share for the current year.
An institutional investor recently bought a new position in Aethlon Medical stock. Millennium Management LLC acquired a new stake in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 200,210 shares of the medical equipment provider’s stock, valued at approximately $238,000. Millennium Management LLC owned 1.20% of Aethlon Medical as of its most recent SEC filing. 7.42% of the stock is owned by institutional investors and hedge funds.
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals.
Recommended Story: What does the Dow Jones Industrial Average (DJIA) measure?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.